Skip to NavigationSkip to content

AstraZeneca asthma therapy tralokinumab flops at Phase 3

Published on 01/11/17 at 09:46am

AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab failed to meet its primary endpoints in the treatment of asthma.

The findings were generated from two Phase 3 trials: STATOS 2 and TROPOS. In STRATOS 2, the anti-interleukin-13 (IL-13) human monoclonal antibody failed to achieve a statistically significant reduction in annual asthma exacerbation rate (AAER) compared to placebo in patients with severe, uncontrolled forms of the disease along with elevated levels of Fractional exhaled Nitric Oxide (FeNO), a biomarker for airway inflammation.

Meanwhile, in the TROPOS study the drug also missed its endpoint in generating a statistically significant reduction in oral corticosteroid use when added to standard of care in patients dependent on them.

“The results are disappointing as we had hoped that tralokinumab would benefit patients with severe asthma, which is a complex disease with limited treatment options today,” commented Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches